EUROPE AND MEA CULTURE TEST FOR HEALTHCARE-ASSOCIATED INFECTIONS MARKET challenges and opportunities

Europe and MEA Culture Test for Healthcare-associated Infections Market, By Product Type (Instruments, Reagents and Consumables), By Test Type (Bacterial Culture Tests, Aerobic Bacteria, Anaerobic Bacteria, Fungal Culture Tests, Viral Culture Tests, and Mixed Infection Tests), By Application (Surgical Site Infections, Bloodstream Infections, Urinary Tract Infections, Respiratory Infections, and Gastrointestinal Infections), By Sample Type (Blood, Urine, Stool, Tissue, and Others), By End User (Hospitals & Clinics, Nursing Homes, Diagnostic Laboratories, Research Institutions, Ambulatory Surgical Centers, and Others)

The Europe and MEA culture test for healthcare-associated infections market is expected to witness high growth over the forecast period owing to rising geriatric population and increasing surgical procedures. Stringent regulations regarding sterilization and disinfection of medical devices will also propel market expansion. Growing number of multi-drug-resistant pathogens and need for correct antimicrobial treatment presents an opportune environment for culture testing.
However, budgetary constraints faced by various healthcare facilities in the Middle East may hamper Europe and MEA culture test for healthcare-associated infections market growth. Lack of reimbursement policies further restrain wider culture testing adoption. Lack of skilled professionals to perform the tests adds to the challenge.
Germany dominates Europe currently due to strong healthcare system and healthcare expenditure. The U.K. also captures sizable share due to high burden of HAIs. Growing public awareness about HAIs boosts demand. Italy is projected to witness the fastest growth owing to rising medical tourism and number of knee and hip replacement surgeries. In the MEA region, GCC countries offer lucrative opportunities for players supported by improved accessibility and quality of care.